Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thursday, March 16th, 2017
March 09 2017 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating diseases,
today announced that it will release Fourth Quarter and Year-End
2016 financial results after market close on Wednesday, March
15, 2017. Further, Catalyst management will host an
investment-community conference call at 8:30 a.m.
EDT on Thursday, March 16th, 2017 to discuss the
financial results and to provide a corporate update.
Investors who wish to participate in the
conference call may do so by dialing (877) 407-8912 for domestic
and Canadian callers or (201) 689-8059 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.catalystpharma.com and clicking on the
webcast link on the Investors home page.
A webcast replay will be available on the
Catalyst website for 30 days following the call by visiting the
Investor page of the company's website
at www.catalystpharma.com.
About Catalyst
Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating diseases, including
Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic
syndromes (CMS), and infantile spasms. Firdapse® has received
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) for the treatment of LEMS and Orphan Drug
designation for LEMS, CMS and myasthenia gravis. Firdapse is the
first and only approved drug in Europe for symptomatic treatment in
adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms, and possibly refractory Tourette's
Disorder. CPP-115 has been granted U.S. orphan drug designation for
the treatment of infantile spasms by the FDA and has been granted
E.U. orphan medicinal product designation for the treatment of West
Syndrome by the European Commission. In addition, Catalyst is
developing a generic version of Sabril® (vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2015 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 529-2522
pmcenany@catalystpharma.com
Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From May 2023 to May 2024